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The SARS-CoV spike glycoprotein (S) is the main target of the protective immune response in humans and animal models of SARS. Here, we
demonstrated that efficient expression of S from the wild-type spike gene in cultured cells required the use of improved plasmid vectors containing
donor and acceptor splice sites, as well as heterologous viral RNA export elements, such as the CTE of Mazon-Pfizer monkey virus or the PRE of
Woodchuck hepatitis virus (WPRE). The presence of both splice sites and WPRE markedly improved the immunogenicity of S-based DNA
vaccines against SARS. Upon immunization of mice with low doses (2 μg) of naked DNA, only intron and WPRE-containing vectors could
induce neutralizing anti-S antibodies and provide protection against challenge with SARS-CoV. Our observations are likely to be useful for the
construction of plasmid and viral vectors designed for optimal expression of intronless genes derived from cytoplasmic RNA viruses.
© 2007 Elsevier Inc. All rights reserved.Keywords: Coronavirus; Severe acute respiratory syndrome; Spike glycoprotein; Viral RNA export element; CTE; WPRE; DNA vaccineIntroduction
A severe, contagious and atypic pneumopathy, named severe
acute respiratory syndrome (SARS), emerged in Southern
China in late 2002. The etiological agent was found to be a new
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doi:10.1016/j.virol.2007.01.0122003, the virus spread to 29 different countries and was
responsible for 8096 clinical cases, leading to 774 deaths
(WHO, 21 April 2004, posting date).
The mechanisms of SARS-CoV introduction into humans
are largely unknown. SARS-CoV-like viruses have been
isolated from caged Himalayan palm civets and raccoon dogs
in live-animal markets in China (Guan et al., 2003; Kan et al.,
2005). Evidences for direct transmission of SARS-CoV-like
viruses from these animals to humans have been reported (Song
et al., 2005; The Chinese SARS Molecular Epidemiology
Consortium, 2004). However, recent studies suggested that
civets may have served only as an amplification host for SARS-
CoVand the existence of an upstream wild animal reservoir has
been proposed (Tu et al., 2004; Wu et al., 2005). Consistent with
this hypothesis, SARS-CoV like viruses sharing more than 88%
nucleotide identities with SARS-CoV have been isolated from
horseshoe bats in mainland China (Li et al., 2005) and Hong
Fig. 1. Transient expression of the SARS-CoV spike protein following plasmid
DNA transfection. Subconfluent monolayers of Vero E6 cells were transfected
with empty (−) or S (+) expression plasmids. At 48 h post-transfection, whole
cell extracts were prepared in Laemmli sample buffer, separated by SDS-PAGE
as indicated (lanes 1 to 4) and analyzed byWestern blot as described in Materials
and methods using rabbit polyclonal antibodies directed against the S protein.
Alternatively, VeroE6 cells were infected with VVTF7-3 at a MOI of 5,
transfected 1 h later with the indicated construct and analyzed for S expression
18 h thereafter (lanes 5 and 6). As controls, whole cell extracts prepared from
VeroE6 cells either mock infected (lane 7) or infected with SARS-CoV (lane 8)
were analyzed. The position of the molecular weight markers is shown on the
right of the gel (kDa).
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CoV is a matter of concern and an efficient vaccine would be the
most effective way to control a new epidemic.
Similar to other coronaviruses, SARS-CoV is an enveloped
positive-strand RNA virus. Its large single-stranded genome,
29.7 kb in length, encodes the replicase polyproteins, small
accessory proteins and four major structural proteins: the
nucleoprotein (N), the small envelope protein (E), the
membrane protein (M), and a large, club-shaped spike protein
(S). The SARS-CoV spike protein is a type-I transmembrane
glycoprotein consisting of 1255 amino acids (a.a.), with a
molecular weight of ∼180 kDa. As predicted by sequence
analysis, it consists of four domains: a signal sequence (a.a. 1 to
14), a large ectodomain comprised of amino-acids 15 to 1190
with 23 potential N-glycosylation sites, a transmembrane
domain (a.a. 1191 to 1227), and a short cytoplasmic tail of 28
a.a. (Ksiazek et al., 2003; Rota et al., 2003). The S protein
mediates many of the biological properties of the virus,
including viral entry: binding to cellular receptors, ACE2 (Li
et al., 2003) and L-SIGN (Jeffers et al., 2004), penetration and
fusion between the viral and cellular membranes (Matsuyama et
al., 2005; Petit et al., 2005; Simmons et al., 2005). It is also
associated with host range and tissue tropism (Giroglou et al.,
2004; Qu et al., 2005), as for other coronaviruses (Casais et al.,
2003; Haijema et al., 2003; Kuo et al., 2000).
The S protein of SARS-CoV is a candidate antigen for
vaccine development, as it is the main target for neutralizing
antibodies in human patients (He et al., 2005; Nie et al., 2004;
Temperton, 2005; Traggiai et al., 2004). Moreover, passive
immunization studies demonstrated that spike-specific neutra-
lizing antibodies are protective in the mouse (Subbarao et al.,
2004) and ferret (ter Meulen et al., 2004) animal models.
Accordingly, several candidate vaccines relying on the induc-
tion of spike-specific neutralizing antibodies have been reported
to induce a protective immune response in various animal
models (Bisht et al., 2004, 2005; Buchholz et al., 2004;
Bukreyev et al., 2004; Chen et al., 2005; Yang et al., 2004).
Efficient expression of intronless genes from plasmid or viral
vectors may require the presence of additional cis-acting
regulatory modules within the expression cassettes, such as
splice sites (SS), retroviral constitutive transport elements
(CTE) and hepadnaviral posttranscriptional regulatory elements
(PRE). The most studied of these latter viral elements are the
CTE of Mason-Pfizer Monkey virus (MPMV-CTE) (Rizvi et
al., 1996) and the PRE of Woodchuck Hepatitis virus (WPRE)
(Donello et al., 1998) and both have been successfully used for
that purpose (Loeb et al., 1999; Tan et al., 1995; Wodrich et al.,
2000; Zufferey et al., 1999). However, the optimal choice of
posttranscriptional enhancer modules depends on the type of
cDNA to be expressed (Schambach et al., 2000). Whether this
strategy may apply to the expression of genes from cytoplasm-
replicating RNA viruses, which mRNAs are not naturally
processed by splicing and nuclear-export machineries, remains
to be determined.
In the present study, we report the construction of a series of
DNA expression vectors containing the wild-type S coding
sequence. The influence of SS, MPMV-CTE or WPRE onexpression of S protein in transfected cells and on induction of a
protective SARS-CoV-specific immunity in mice after naked
DNA immunization are compared. We found that WPRE
together with SS allowed most efficient expression of S in 293T
and VeroE6 cells whereas CTE had a slight to moderate effect
depending on the cell line. Furthermore, dose range experiments
demonstrated that, when administered to mice, DNA plasmid
vectors with WPRE induced the highest levels of anti-S
antibodies and protection towards a challenge with live
SARS-CoV.
Results
Construction of SARS-CoV S expression vectors and
comparison of S expression in transfected primate cells
The coding region of SARS-CoV S protein was amplified by
RT-PCR from the broncho-alveolar lavage of a patient
hospitalized with probable SARS at the Hanoï French Hospital
(Vietnam) in 2003 and cloned into pcDNA3.1 and pCI
expression vectors under the control of the cytomegalovirus
(CMV) immediate/early promoter, yielding pcDNA-S and pCI-
S plasmids, respectively (see Fig. 2A).
We initially tested protein expression driven by these vectors
in transiently transfected Vero E6 cells, which are permissive for
SARS-CoV replication, thus allowing mature expression of
essential SARS-CoV genes. pcDNA-S did not induce detect-
able levels of S protein either by immunoblotting using an S-
specific rabbit antiserum (Fig. 1, lane 2) or by indirect
immunofluorescence (data not shown). This was not due to
inadequate sensitivity of the detection methods, since S as
Fig. 2. Improvement of SARS-CoV spike protein expression by viral export
elements. (A) Schematic representation of S expression plasmids. Viral export
elements were inserted in pcDNA-S and pCI-S plasmids, downstream of the S
ORF sequence and upstream of the polyadenylation signal (pA). SP: signal
peptide. TM: transmembrane domain. SD-SA: donor and acceptor splice sites,
respectively. BGH: bovine growth hormone. SV40: Simian Virus 40. WPRE:
Woodchuck hepatitis virus post-transcriptional element. CTE: constitutive
transport element from Mason Pfizer Monkey Virus. Subconfluent monolayers
of VeroE6 (B) and 293T (C) cells were transfected with the indicated S
expression constructs. At 48 h post-transfection, whole cell extracts were
analyzed by Western blotting as in Fig. 1. The position of the molecular weight
markers is shown on the right of the gel (kDa).
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the expected size of ∼180 kDa (Fig. 1, lane 8). In addition,
potential defect in the pcDNA-S construct, low transfection
efficiency or other flaws could be excluded, since pcDNA-S
induced high levels of S expression from the T7 RNA
polymerase promoter, when T7 RNA polymerase was
expressed in Vero E6 cells after superinfection with VV-TF7.3
recombinant vaccinia virus (Fig. 1, lane 6).
In contrast, S protein expression could be detected in Vero
E6 cells after transfection of the pCI-S construct (Fig. 1, lane 4).
Similar data were obtained in 293T cells (see Fig. 2B). The pCI-
S construct differs markedly from the pcDNA-S construct by
the presence of a chimeric intron between the CMV promoter
and the S coding sequence. The inserted intron is composed of
the donor site from the first intron of the human β-globin gene
and the branch and acceptor site from the intron of an
immunoglobulin gene (Promega, January 2004, revision date).
These results suggested that the presence of an intron is required
for expression of the SARS-CoV S gene, when the correspond-
ing mRNA is synthesized in the nucleus of transfected cells.
However, expression levels driven by pCI-S remained low as
compared to the levels observed in the T7 RNA polymerase
based expression system (Fig. 1, compare lanes 4 and 6). In the
latter (Fuerst et al., 1986), transcription takes place primarily in
the cytoplasm, suggesting that S mRNA might be abnormally
processed after synthesis in the nucleus or inefficiently exported
to the cytoplasm.
Enhancement of SARS-CoV S protein expression with viral
export elements
Cis-acting viral export elements such as the CTE of Mason-
Pfizer Monkey Virus (MPMV-CTE), and the PRE of Wood-
chuck hepatitis virus (WPRE) have been shown to increase the
nuclear export of mRNAs, resulting in higher protein expres-
sion levels (Bray et al., 1994; Donello et al., 1998; Gruter et al.,
1998; Popa et al., 2002). Therefore, MPMV-CTE and WPRE
sequences were inserted in both pcDNA-S and pCI-S plasmids
downstream of the S coding sequence and upstream of the
polyadenylation sequence (Fig. 2A).
Immunoblot analysis of cell lysates prepared from trans-
fected VeroE6 and 293T cells are shown in Figs. 2B and C,
respectively. S expression remained below detectable levels
whatever viral export element inserted in the pcDNA-S plasmid.
In marked contrast, both CTE and WPRE increased S
expression when inserted in the pCI-S plasmid. The most
dramatic effect was observed upon pCI-S-WPRE transfection
into either VeroE6 or 293T cells. Similar data were obtained in
simian FRhK-4 and hamster BHK cells (data not shown). To
evaluate more accurately the impact of CTE and WPRE on S
production, protein expression levels were quantified from the
luminescence signals recorded with a cooled CCD camera
(Table 1). As compared to pCI-S, a 12- to 42-fold increase for
the WPRE-containing pCI plasmid was observed, regardless of
the cell lines used, while CTE had more impact on S ex-
pression in VeroE6 cells (9- to 26-fold increase) than in 293T
cells (4-fold increase).Expression of S at the cell surface was examined by FACS
analysis performed on non-permeabilized 293T cells at 48 h
post-transfection. Less than 5% of cells transfected with either
plasmid from the pcDNA-S series were stained by polyclonal
mouse anti-S antibodies (Fig. 3, upper left panel and data not
shown), while 50% of cells transfected with the pCI-S-WPRE
construct were found positive (Fig. 3, lower right panel). In
agreement with immunoblotting data, WPRE was much more
Table 1
Relative quantitative expression of S protein in transiently transfected cells
Plasmid S levels (arbitrary units) a
VeroE6 cells b 293T cells b
Expt. 1 c Expt. 2 Expt. 1 Expt. 2
pCI NA NA NA NA
pCI-S 1.0±0.1 1.0 1.0 1.0
pCI-S-CTE 9.8±0.9 26.4 4.6 4.0
pCI-S-WPRE 20.1±2.0 42.3 27.6 12.8
NA: not applicable.
a Protein expression levels were quantified from the captured gel image as
described in Materials and methods and are indicated in arbitrary units (1= the
value measured in pCI-S-transfected cells for a given cell line).
b Data from two independent experiments are reported.
c Figures are mean±S.D. of duplicate determinations.
291B. Callendret et al. / Virology 363 (2007) 288–302efficient than CTE in enhancing S expression from pCI-S DNAs
at the surface of 293T cells. Levels of S produced upon
transfection of pCI-S-CTE and pCI-S-WPRE were 2- and 11-
fold higher, respectively, than those produced upon transfection
of pCI-S.
To analyze whether enhanced S expression correlated with
increased S mRNA levels, we performed Northern blot analysis
of cytoplasmic fractions prepared 24 or 48 h post-transfection of
VeroE6 and 293T cells. S mRNAs were detected with a mixtureFig. 3. Analysis of S protein expression at the surface of transfected cells.
Subconfluent monolayers of 293T cells were transfected with each of the
indicated S expression plasmids. At 48 h post-transfection, cells were detached
from the plates and labeled with anti-S mouse polyclonal antibodies and FITC-
conjugated anti-mouse IgG antibodies. Flow cytometry analysis was performed
on a FACScalibur fluorocytometer. pCI-transfected 293T cells were used as
control (dotted lines). S expression at the cell surface of transfected cells was
quantified as the mean fluorescence intensity of the fraction of S-expressing
cells (bar) and is indicated in each histogram in arbitrary units (1=mean
intensity measured in pCI-S-transfected cells).of three S-specific probes and their relative abundance was
calculated using β-actin mRNA levels as an internal control. A
representative experiment is shown in Fig. 4 for mRNAs
prepared 48 h after transfection of 293T cells. No S-specific
mRNA was detected in the cytoplasm of cells transfected with
any pcDNA-S-derived plasmid or empty plasmid, in agree-
ment with the lack of S expression. S mRNAs of the expected
size were observed with plasmids of the pCI-S series. Thus,
cytoplasmic accumulation of S mRNA and hence S protein
expression appeared to be dependent on correct splicing.
Surprisingly, CTE had no impact on the amount of cyto-
plasmic S mRNAs in VeroE6 and 293T cells, neither at 24 h
nor at 48 h post-transfection (Fig. 4 and data not shown). In
contrast, WPRE increased mRNA levels in 293T cells by 3-
fold at both 24 h (data not shown) and 48 h (Fig. 4) post-
transfection, and transiently increased mRNA levels in VeroE6
cells at 24 h post-transfection (2.7 fold increase; data not
shown).
Altogether, our results showed that both CTE and WPRE
have a greater effect at the protein level than at the mRNA level
(compare Fig. 3 and Table 1 to Fig. 4) and thus promote SARS-
CoV spike protein expression by increasing mRNA translation.
In all cell lines examined, the impact of WPRE on S protein
expression was consistently better than that of CTE, reflecting
synergistic effects of this element on cytoplasmic mRNA levels
and mRNA translation.Fig. 4. Analysis of S mRNA in transfected cells. Subconfluent monolayers of
293T cells were transfected with each of the indicated S expression plasmids.
At 48 h post-transfection, cytoplasmic RNA was prepared and analysed by
Northern blot for the presence of S mRNAs with a mixture of negative sense
riboprobes specific for S sequences, as described in Materials and methods.
The position of molecular weight markers is indicated on the side. For
normalization, Northern blot analysis was performed in parallel using a
negative sense β-actin specific riboprobe. The amounts of S specific RNAs of
the expected size (stars) and β-actin RNAs were quantified and the calculated
S/β-actin specific mRNA ratios are indicated below the images (1=ratio found
in pCI-S transfected cells).
Fig. 5. Efficient fusion of S-protein- and ACE2-expressing 293Tcells. 293Tcells constitutively expressing GFP (effector cells), were transfected with pCI-S-WPRE or,
as control, with the empty pCI plasmid. 293T cells transfected with pCMV-DsRed (target cells) were also transfected with either pcDNA-ACE2 or, as control, with the
empty pcDNA plasmid. At 36 h post-transfection, target and effector cells were mixed at a 1:1 ratio and analysed by flow cytometry for GFP and DsRed expression
12 h thereafter. The indicated percentage of fusion was measured as the ratio between double-stained cells (upper right quadrant) and red target cells (lower plus upper
right quadrant). A: Effector cells transfected with pCI mixed with target cells transfected with pcDNA. B: Effector cells transfected with pCI-S-WPRE mixed with
target cells transfected with pcDNA. C: Effector cells transfected with pCI mixed with target cells transfected with pcDNA-ACE2. D: Effector cells transfected with
pCI-S-WPRE mixed with target cells transfected with pcDNA-ACE2.
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studies of the protein and serological surveillance of SARS
Having shown that the SARS-CoV S protein can be
efficiently expressed at the cell surface by using the WPRE
element, we sought to further test whether the S protein
expressed in this system was functional and antigenically
relevant.
We first evaluated the capacity of the WPRE-expressed S
protein to induce receptor-dependent cell-to-cell fusion. WeFig. 6. Serological evaluation of convalescent human sera using S-protein-expressin
pCI (A, B) or pCI-S-WPRE (C to F). At 48 h post-transfection, cells were stained as d
B, E), or serum collected from patient B 8 days (#032703; C) or 29 days (#033153; F)
from a healthy donor (TV262; A, D).took advantage of the fact that, under our experimental
conditions, co-transfection of 293T cells with two different
expression plasmids allowed expression of both encoded
proteins in more than 90% of the transfected cell population
(data not shown). Thus, target cells were prepared by co-
transfection of 293T cells with pcDNA-DsRed and pcDNA3-
ACE2, which allow expression of the fluorescent DsRed protein
and the ACE2 SARS-CoV receptor, respectively (Li et al.,
2003). Concurrently, effector cells were prepared by transfec-
tion of 293T-GFP cells with the pCI-S-WPRE plasmid. Theg VeroE6 cells. Subconfluent monolayers of VeroE6 cells were transfected with
escribed in Materials and methods using either serum from patient A (#033168;
after the onset of SARS symptoms, or serum collected before the SARS epidemic
Fig. 7. WPRE enhances anti-S antibody responses in mice immunized with low
doses of plasmid DNA. Groups of 6 BALB/c mice were injected twice
intramuscularly at 4-week interval with 2, 10 or 50 μg of S expression plasmid
DNA as indicated, or with 50 μg of pCI plasmid DNA as control. Immune sera
were collected 3 weeks after the second injection. SARS-CoV specific IgG
antibody titers were determined by indirect ELISA using SARS-CoV infected
VeroE6 cell lysates as the capture antigen, as described in Materials and
methods. Values for each individual mouse are represented with black circles,
and means with horizontal bars. The detection limit of the assay is indicated by a
dotted line.
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evaluated by FACS analysis (Fig. 5). We found that no cell-to-
cell fusion occurred when S-expressing effector cells were
mixed with mock-transfected target cells (panel B) or when
mock-transfected effector cells were mixed with ACE2-
expressing target cells (panel C), as the percentage of green-
and red-stained cells did not increase above background (panel
A). In contrast, more than 45% of target cells expressing ACE2
did fuse with effector cells expressing S (panel D).
Next, we evaluated the antigenicity of the WPRE-expressed
S protein using convalescent human sera. VeroE6 cells were
transfected with pCI-S-WPRE or pCI as a control, and immuno-
fluorescence assays (IFA) were carried out using three SARS
convalescent human sera and two normal human sera (Fig. 6).
S-expressing VeroE6 cells were readily stained with convales-
cent sera from the SARS cases (panels E, F and data not shown)
but not with sera from healthy blood donors (panel D as an
example), while control Vero cells showed no staining (panels
A, B). In addition, this S-protein based IFA allowed to monitor
seroconversion of patients for SARS, using serum samples
taken during the acute and convalescent phases of the disease
(panels C and F, respectively as an example).
Altogether, our results indicate that WPRE-mediated expres-
sion of S is qualitatively and quantitatively relevant, since the
resulting polypeptide is capable of inducing cell-to-cell fusion
and is efficiently recognized by convalescent human sera.
Induction of anti-S antibody response in mice immunized with
WPRE-enhanced naked DNA vaccine
In order to compare the capacity of CTE and WPRE to
enhance the efficacy of naked DNA vaccine, we performed a
dose response experiment. Female BALB/c mice were
immunized by intramuscular injection of 2, 10 or 50 μg of
pCI-S, pCI-S-CTE or pCI-S-WPRE naked plasmid DNA. This
dose range extended from suboptimal to optimal doses of
typical plasmid DNA vaccine in mice and was selected
according to our preliminary experiments (data not shown)
and published data (Fu et al., 1999; Ulmer et al., 1994; Wang et
al., 2000). As control, a group of mice was injected with 50 μg
of DNA from the parental pCI plasmid. Mice were boosted at
week 4 with the same dose of DNA and the resulting immune
responses were analyzed 3 weeks later. Anti-S serum IgG
antibody titers were determined for each individual mice by
indirect ELISA using SARS-CoV-infected VeroE6 cell lysates
as native antigens (Fig. 7). At the optimal 50-μg dose, each of
the three S expression plasmids induced a high anti-S IgG
response. The log10 serum IgG titers were 3.7±0.2 for both
pCI-S and pCI-S-CTE-immunized mice and 3.9±0.1 for pCI-S-
WPRE-immunized mice, indicating that pCI-S-WPRE induced
significantly higher (∼2-fold, p<0.05) anti-S IgG levels than
pCI-S and pCI-S-CTE. At the 10-μg suboptimal dose of
plasmid DNA, pCI-S-WPRE induced a much higher and more
consistent response across mice (3.6±0.2 log10 titer) than pCI-
S (2.8±0.4 log10 titer, p<0.01) and pCI-S-CTE (2.4±1.0
log10 titer, p<0.03). At the lowest dose (2 μg plasmid DNA per
mouse), both pCI-S and pCI-S-CTE failed to induce anydetectable anti-S antibodies (log10 titer <0.9) with the
exception of a single mouse (1.4 log10 titer) out of eight pCI-
S-CTE-immunized mice, whereas anti-S IgG titers remained
high (3.1±0.5 log10 titer) for all pCI-S-WPRE-immunized
mice. Thus, the anti-S antibody levels induced by pCI-S-CTE
were comparable to those induced by the pCI-S construct, with
no statistically significant differences at any dose tested
(p>0.3).
This dose response experiment clearly demonstrates that
WPRE strongly enhances the immunogenicity of an S-based
anti-SARS naked DNA vaccine in mice, whereas CTE has no
effect. The most remarkable effect was observed at the very low
dose of 2 μg naked DNA per mouse, for which the WPRE-
enhanced DNA vaccine only was able to induce high levels of
anti-SARS antibodies.
Induction of complete protection of mice against a SARS-CoV
challenge by a low dose of WPRE-enhanced DNA vaccine
To assess whether a low dose of the WPRE-enhanced DNA
vaccine could induce protective immunity against SARS,
BALB/c mice were injected three times with 2 μg of plasmid
DNA at 4-week intervals. The mice received the various DNA
constructs as described above. First, sera were sampled at
3 weeks post-immunization, and we examined whether the
antibody response was capable of SARS-CoV neutralization.
Neutralizing antibody titers remained below the detection level
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8A). In contrast, significant levels of SARS-CoV neutralizing
antibodies were measured in 7 out of 8 mice immunized with
pCI-S-WPRE plasmid DNA. Next, at 8 weeks post-immuniza-
tion, mice were transferred to a BSL-4 animal facility and
challenged by intranasal inoculation of 105 pfu of SARS-CoV.Fig. 8. WPRE is required for protection of mice from SARS-CoV challenge
upon immunization with low-dose plasmid DNA. Groups of 8 BALB/c mice
were injected three times intramuscularly at 4-week interval with 2 μg of S
expression plasmid DNA as indicated, or with 2 μg of pCI plasmid DNA as
control. Immune sera were collected 3 weeks after the third injection and
assayed for neutralizing antibodies against SARS-CoV. Neutralization titers
(A) were calculated as the reciprocal of the highest dilution of each individual
serum, which completely prevented SARS-CoV CPE in 50% of the wells, as
described in Materials and methods. Eight weeks after the third DNA injection,
mice were challenged intranasally with SARS-CoV (105 pfu/mouse). Two days
after inoculation, mice were euthanized. Lung homogenates were prepared and
titrated for infectious SARS-CoV by plaque assay on VeroE6 cells. Viral titers
were expressed as log10 (pfu/lungs) for individual mice (B). Values for each
individual mouse are represented with black circles, and means with horizontal
bars. The detection limits of the assays are indicated by a dotted line. Data
shown are from one experiment representative of two.Viral loads in the lungs were evaluated 2 days later (Fig. 8B).
No significant difference was found in the viral titers observed
in mice injected with pCI-S (5.8±0.5 log10 pfu/lungs), pCI-S-
CTE (5.9±0.3 log10 pfu/lungs) or with control pCI (5.3±0.6
log10 pfu/lungs). In sharp contrast, immunization with pCI-S-
WPRE plasmid DNA conferred almost complete protection
with no infectious virus detectable in 7 out of 8 mice (log10 pfu/
lungs <1.8) and a very low residual titer in a single mouse
(p<10−8).
These studies clearly indicate that the WPRE-enhanced
SARS DNA vaccine is most effective in inducing complete
protective immunity, providing protection against SARS-CoV
challenge after low-dose injection of naked plasmid DNA.
Discussion
To our knowledge, the vast majority of published studies
relying on the transient expression of the spike protein of all
coronaviruses before the SARS-CoV epidemic was recognized,
involved the use of either T7 RNA polymerase-based
expression systems or viral expression vectors such as
recombinant Sindbis or vaccinia viruses (Horsburgh and
Brown, 1995; Krueger et al., 2001; Narayanan et al., 2003;
Pulford and Britton, 1991; Vennema et al., 1996; Yoo and
Deregt, 2001). This may be indicative of the difficulty to
express efficiently the long coronavirus S gene following
transient transfection of mammalian cells with conventional
DNA expression vectors, that lead to mRNA synthesis in the
cell nucleus. Consistent with this hypothesis, we also found
that the SARS-CoV S gene is not expressed at detectable levels
when cloned into the classical pcDNA mammalian expression
vector under the control of a nuclear polymerase II promoter
(Fig. 1), whereas it is expressed efficiently from a recombinant
vaccinia virus (V. Lorin, B. Callendret, S. van der Werf and N.
Escriou, unpublished data). Likewise, it has been reported that
the S protein from SARS-CoV is poorly expressed following
DNA transfection (Chang et al., 2006; Hofmann et al., 2004;
Qin et al., 2004; Simmons et al., 2004), hence most published
studies used T7 RNA polymerase-based expression systems
(Schwegmann-Wessels et al., 2004; Xiao et al., 2003) or syn-
thetic genes optimized for human codon usage (Huang et al.,
2004; Qin et al., 2004; Zhi et al., 2005). Here, we describe the
design and use of a modified DNA expression vector to
enhance SARS-CoV S expression in mammalian cells. This
DNA vector contains the CMV immediate/early promoter, a
chimeric intron and a cis-acting CTE or WPRE element. We
demonstrate that this vector permits the expression of high
levels of S at the cell surface of transiently transfected cells,
that are compatible with functional and antigenic characteriza-
tion of the S protein. In addition, this low-cost and easy-to-use
expression vector allowed us to develop a cell-to-cell fusion
assay and an immunofluorescence assay, which may prove
useful for the study of cellular and viral determinants of S-
induced membrane fusion and for the sensitive and specific
routine diagnosis of SARS seroconversion.
Detectable expression of both spike mRNA and protein in
transfected cells required the use of plasmid vectors containing
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are consistent with data reported by Hofmann et al. (2004),
Simmons et al. (2004) and Broer et al. (2006), who employed
the pCAGG or phCMV vectors to achieve detectable S
expression. Both pCAGG and phCMV vectors also harbor
donor and acceptor splice sites downstream of a polymerase II
promoter. Altogether, these data indicate that cytoplasmic
accumulation of S mRNA, hence S protein expression, are
absolutely dependent on splicing. Most genes in higher
eucaryotes contain at least one intron and many studies have
clearly shown that constitutively spliced introns or the presence
of a heterologous intron of either viral or cellular origin may be
required for optimal gene expression in a variety of systems,
including transient expression in mammalian tissue culture
cells. The importance of splicing for expression of a given gene
appears to depend on several factors such as intron and exon
identity and cell type (Buchman and Berg, 1988; Petitclerc et
al., 1995). Albeit much less documented, the expression of
intronless genes of bacterial and viral origin can also be
enhanced by including introns within mammalian vectors
(Huang and Gorman, 1990; Huang and Yen, 1995). Although
it has been suggested that introns alter the nucleocytoplasmic
distribution of mRNAs, more recent data indicate that splicing
rather enhances both mRNA production and translational
efficiency (Lu and Cullen, 2003; Nott et al., 2003). Our results
extend these observations and indicate that the nuclear
expression of naturally intronless genes derived from RNA
viruses that replicate in the cell cytoplasm may follow the same
requirements (presence of an intron) for efficient mRNA
accumulation in the cytoplasm.
Although cis-acting viral export elements could compensate
for the lack of an intron in the expression of the human β-globin
cDNA from a retroviral vector (Schambach et al., 2000), CTE
and WPRE did not permit efficient expression of the SARS-
CoV S gene from the pcDNA vector and both S mRNA and
protein remained undetectable. However, a remarkable boost in
S expression was observed when CTE or WPRE was combined
with an intron within the pCI vector (Figs. 2 and 3). Interest-
ingly, we did not observe any effect of CTE at the level of S
mRNA production in 293T and VeroE6 cells. This was
unexpected because CTE-enhanced expression has been linked
to CTE-mediated export of mRNAs, conferring rev-indepen-
dence to HIV-1 gag expression (Bray et al., 1994; Wodrich et
al., 2000) and contributing to overcome inhibitory elements of
HPV-16 L1 mRNA (Tan et al., 1995). Our results rather support
the hypothesis raised by Schambach et al. (2000), according to
which CTE is much more efficient in promoting export of
unspliced intron-containing retroviral RNA transcripts (Ernst et
al., 1997a; Gruter et al., 1998; Kang and Cullen, 1999), than in
facilitating the transport of spliced mRNA. In contrast, WPRE
enhanced cytoplasmic S mRNA levels by 3-fold in both 293T
and VeroE6 cells. Both CTE and WPRE have an export
function, but they differ by the mechanisms involved in that
CTE binds to the Tap nuclear mRNA export factor (Gruter et al.,
1998), while WPRE recruits the cellular Crm1 RNA export
factor (Popa et al., 2002). The observation that Tap is also
implicated in the export of cellular spliced mRNAs from thenucleus suggests that CTE RNA and spliced mRNAs share a
common nuclear export pathway (Braun et al., 1999). This may
explain the absence of synergy between intron and CTE in
enhancing the cytoplasmic levels of spliced S mRNA in both
293T and VeroE6 cells (Fig. 4). In contrast, WPRE RNA and
spliced mRNAs use different factors for nuclear export and our
data indicate that these may act synergistically to enhance the
cytoplasmic expression of an intron-containing WPRE RNA
(Fig. 4). A similar observation was made by Schambach et al.,
who reported that elevated expression of the human multidrug
resistance gene (MDR1) mRNA in SW480 cells depends on the
presence of both an intron and WPRE (Schambach et al., 2000).
The effect of CTE and WPRE was more pronounced on S
protein levels than on S cytoplasmic mRNAs levels (compare
Fig. 3 and Table 1 to Fig. 4), indicating that, in addition to their
initially recognized role in mRNA export, CTE and WPRE also
act by promoting efficient mRNA translation. Such a role for
CTE in mRNA translation has been recently suggested by the
groups of Boris-Lawrie and Hammarskjöld (Coyle et al., 2003;
Hull and Boris-Lawrie, 2003; Jin et al., 2003). In contrast, it is
not in full agreement with the common view that WPRE exerts
its effect on protein expression mainly by enhancing 3′ mRNA
processing and nucleocytoplasmic transport (Donello et al.,
1998; Loeb et al., 1999; Zufferey et al., 1999). To our
knowledge, a single report suggested that WPRE may
contribute to enhanced cytoplasmic utilization of an intronless
EGFP mRNA in addition to its effect on nuclear RNA
processing and RNA export (Schambach et al., 2000).
Interestingly, the closely related Hepatitis B virus PRE has
also been reported to enhance translation of the RNA harboring
this element (Lu and Cullen, 2003).
In conclusion to our in vitro studies, we demonstrated that
the marked enhancing effect of WPRE on S protein expression
from spliced S transcripts is due to the synergistic effect of
increased levels of cytoplasmic messenger RNA and increased
cytoplasmic utilization of these mRNAs. Our data provide a
likely explanation to the observations of Wang et al. (2003) who
reported that WPRE improved the production of the E2 protein
of the type 2 bovine diarrhea virus (a cytoplasmic RNA virus)
when expressed in transiently transfected cells or from a
recombinant herpesvirus. Our results have important implica-
tions for the construction of plasmid and viral vectors optimally
designed for the expression of intronless genes from cytoplas-
mic RNA viruses.
Successful expression of full-length S protein in mammalian
cells was alternatively achieved by others by using codon-
optimized synthetic genes (Huang et al., 2004; Qin et al., 2004;
Zhi et al., 2005). Codon-usage adaptation most often involves
the substitution of nearly every wobble position for a G or C
nucleotide (Nakamura, October 2006, posting date; Nakamura
et al., 2000), resulting in genes with a much diverse nucleotide
composition and decreased A/T content. Wild-type genes from
viruses with a nuclear life cycle such as HIV-1 or HPV-16
contain regulatory elements evolved to inhibit mRNA cyto-
plasmic accumulation. For HIV-1 Gag, Vpu, Vif (Graf et al.,
2000; Kotsopoulou et al., 2000; Nguyen et al., 2004) or HPV-16
L1 and L2 proteins (Collier et al., 2002; Oberg et al., 2003),
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result in the inactivation of such elements, thus leading to
increased viral protein expression from nuclear DNA expres-
sion vectors. Cytoplasmic viruses, such as SARS-CoV, may
contain cryptic splice sites, mRNA instability motifs such as A/
U-rich elements (AREs), or putative cis-active inhibitory
sequences, which may explain why DNA vector-based expres-
sion of genes from these viruses is dependent on the presence of
heterologous intron and transport elements. It can be hypothe-
sized that codon-usage adaptation is a successful strategy to
express high levels of cytoplasmic virus proteins as the result of
removal of these yet uncharacterized inhibitory elements.
In S-based DNA vaccination experiments, we found that
the presence of an intron was mandatory to induce high titers
of protective neutralizing antibodies in immunized mice (data
not shown). This is in agreement with the absence of S
polypeptide expression in cultured cells from the pcDNA-S
plasmid (Figs. 1–3) and with the weak antibody responses
observed by others in mice immunized with pcDNA-based S
constructs (Wang et al., 2005b). In addition, among published
reports describing full-length-S-based DNA vaccines, only
those based on a codon-optimized gene proved capable of
inducing high titers of neutralizing antibodies in mice (Yang et
al., 2004, 2005; Yi et al., 2005) or rabbits (Wang et al.,
2005a). It is noteworthy that similar observations were
reported recently for replication-defective human adenoviral
vectors containing the wild-type S gene under the control of
the CMV promoter; such recombinant vectors failed to induce
cellular immune responses against spike epitopes, whereas
vectors encoding codon-optimized S protein proved to be
potent immunogens (Zhi et al., 2005). Since expression from
adenoviral vectors relies on nuclear transcription of the foreign
gene, this corroborates our hypothesis that wild-type S mRNA
does not accumulate in the cytoplasm in the absence of a
heterologous intron.
In the present study, we demonstrated that a combination of
an intron and WPRE, but not of an intron and CTE, acted
synergistically in enhancing the immunogenicity of an S-based
anti-SARS DNA vaccine in BALB/c mice. We showed that
10 μg of pCI-S-WPRE induced a SARS-CoV neutralizing
antibody response (log10 titer=2.2±0.2) similar to that induced
by 25 μg of a codon-optimized expression vector, as described
by Yang et al. (2004). Moreover, our in vivo data clearly
indicate that immunization with the WPRE-enhanced vaccine
induced complete protective immunity against challenge
infection with SARS-CoV at doses as low as 2 μg at which
the more conventional DNAvaccine (including intron sequence
but lacking WPRE) did not (Fig. 8). To our knowledge, this is
the first report of a successful DNA vaccination protocol using
the full-length, wild-type S gene of SARS-CoV, without codon
optimization. Whether WPRE could further enhance the
protective efficacy of a DNA vaccine based on a codon-
optimized gene of the SARS-CoV S protein, such as that
reported by Yang et al., is an interesting question which would
deserve additional studies.
It has been reported recently that the presence of WPRE also
markedly enhanced the efficacy of two other DNA vaccines, aviral vaccine based on HA expression in a mouse model of
influenza (Garg et al., 2004), as well as a tumor vaccine in a
mouse model of neuroblastoma metastases (Pertl et al., 2003).
The three studies with the SARS (our study), influenza (Garg et
al., 2004) and neuroblastoma (Pertl et al., 2003) models show
remarkable complementarity in demonstrating that WPRE
enhanced the protective efficacy of DNA vaccines encoding
antigens from the fully-spliced cDNA of a tumor gene and two
naturally intronless genes, one derived from a nucleus-
replicating negative strand RNA virus (influenza virus) and
the other from a cytoplasm-replicating positive strand RNA
virus (SARS-CoV). The mechanisms involved in the enhanced
induction of protective immunity remain stricto sensu to be
investigated but WPRE very likely improves the level of
antigen expression in vivo, as it does in vitro in transient
transfection experiments.
In summary, our data provide valuable information with
respect to the improvement of S protein expression from the
wild-type SARS-CoV gene by using both an intron and the
WPRE post-transcriptional enhancer, and resulting improve-
ment of the immunogenicity of an S-based DNA vaccine.
From a practical point of view, this may help decrease the
amount of plasmid DNA in immunization protocols. As noted
by others (Garg et al., 2004), by lowering the amount of DNA
used in immunization protocols, concerns raised by the use of
DNA vaccines, such as risks posed by integration events into
the host genome or the induction of autoimmune responses
(Cui, 2005), are minimized. Moreover, one of the principal
limitations to DNA vaccine efficacy in large animals, like non-
human primates, may be related to the limited distribution of
DNA within the injected tissue and limited uptake to the
nucleus following injection of DNA vaccine in a relatively
small volume (Dupuis et al., 2000; Otten et al., 2004). These
limitations may be circumvented by the use of efficient DNA
vectors based on a combination of intron and WPRE
enhancer, such as those we describe here. Thus, these
improved plasmid vectors might possibly contribute to the
development of a safe and efficient DNA vaccine against
SARS in humans. Further studies in larger animals, such as
cynomolgus macaques or African Green Monkeys, which
were recently described as suitable animal models for SARS
(Fouchier et al., 2003; Lawler et al., 2006; McAuliffe et al.,
2004; Rowe et al., 2004) could help validate the intron and
WPRE based vectors.
Materials and methods
Cell lines and viruses
FRhK-4 (Fetal Rhesus monkey Kidney), CV-1 and Vero E6
(African Green monkey kidney) cells were grown at 37 °C
under 5% CO2 in complete DMEM [Dulbecco's modified Eagle
medium with 4.5 mg/mL L-glucose, 100 U/mL penicillin and
100 μg/mL streptomycin], supplemented with 5% heat-
inactivated fetal calf serum (FCS) (DMEM-5). 293T (human
kidney) cells were grown in complete DMEM supplemented
with 10% FCS (DMEM-10).
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provided by H.W. Doerr (Institute of Medical Virology,
Frankfurt University Medical School, Germany). Viral stocks
were produced at 35 °C by passage on Vero E6 cell cultures at a
multiplicity of infection (M.O.I.) of 0.01 in complete DMEM
with 2% FCS. All viral stocks were stored at −80 °C and titrated
in a standard limiting dilution assay on Vero E6 cell monolayers
in 96-well microtiter plates. Infectious titers were determined as
50% tissue culture infective doses (TCID50) according to Reed
and Muench (Reed and Muench, 1938). All work involving
infectious SARS-CoV was performed in an enhanced biosafety
level 3 containment laboratory with rigorous safety procedures
according to WHO guidelines.
VV-TF7.3 is a recombinant vaccinia virus encoding the T7
RNA polymerase (Fuerst et al., 1986) and was provided by B.
Moss (National Institute of Health, Bethesda, U.S.A.). VV-
TF7.3 was propagated at 35 °C by passage on CV-1 monolayers
at an MOI of 0.1 and titrated by a standard plaque assay.
S gene expression plasmids
The S gene of SARS-CoV was obtained directly from the
viral RNA extracted with the QIAamp Viral RNA mini kit
(Qiagen) from the broncho-alveolar lavage (#031589 specimen)
of a patient hospitalized with a diagnosis of probable SARS at
the Hanoï French Hospital, Vietnam. Briefly, after reverse
transcription of the RNA, overlapping S cDNA fragments were
produced by nested PCR and the cDNA fragment representing
the complete S gene sequence (nt 21406–25348) was
assembled from clones harboring the consensus protein
sequence as deduced by direct sequencing of the amplicons
from specimen #031589 (Nal et al., 2005). The resulting
plasmid pSARS-S was used as the source of S cDNA for
subsequent cloning into mammalian expression vectors.
Comparison of its sequence with the S sequences of the
TOR2 (GenBank accession no. AY274119.3) and Urbani
(GenBank accession no. AY278741.1) isolates revealed one
amino-acid difference at position 577: Alanine for TOR2 and
Serine for Urbani and 031589. The DNA sequence coding for
the S protein was amplified by PCR with the PWO polymerase
(Roche) using pSARS-S plasmid as a template and oligonu-
cleotides 5′-ATAGGATCCA CCATGTTTAT TTTCTTATTA
TTTCTTACTC TCACT-3′ and 5′-ATACTCGAGT TATGTG-
TAAT GTAATTTGAC ACCCTTG-3′ containing BamHI and
XhoI restrictions sites. After digestion with BamHI and XhoI,
the resulting DNA fragment was inserted at the corresponding
sites of the pcDNA3.1(+) vector (Invitrogen), yielding plasmid
pcDNA-S. Next, the S insert was subcloned between the NheI
and XhoI sites of the pCI plasmid (Promega), yielding plasmid
pCI-S.
Plasmids containing the constitutive transport element of
Mazon-Pfizer Monkey Virus (CTE) (Ernst et al., 1997b) or the
post-regulatory element of the Woodchuck Hepatitis Virus
(WPRE) (Donello et al., 1998) were kindly provided by Y.
Jacob and P. Charneau respectively (Institut Pasteur, Paris,
France). The CTE fragment was obtained by digestion of the
relevant plasmid with XhoI and BamHI. The WPRE fragmentwas obtained by digestion of the relevant plasmid with XhoI
and KpnI. These fragments were then inserted downstream the
S ORF sequence between the XhoI and XbaI sites either in
pcDNA-S or in pCI-S plasmids, yielding plasmids pcDNA-S-
CTE, pcDNA-S-WPRE, pCI-S-CTE and pCI-S-WPRE
respectively.
All constructs' inserts were verified by the sequencing of
positive clones using a Big Dye terminator sequencing kit and
an automated sequencer (Applied Biosystems).
Antibodies
Rabbit anti-S polyclonal antibodies
The cDNA encoding amino acids 475 to 1193 of the S
protein was amplified by PCR using the S plasmid as a template
and oligonucleotides 5′-CCCATATGAG TGACCTTGAC
CGGTGCACCA C-3′ and 5′-CCCCCGGGTT TAATATATTG
CTCATATTTT CCC-3′ containing NdeI and XmaI restriction
sites. After digestion with NdeI and XmaI, the resulting DNA
fragment was inserted at the corresponding sites of the bacterial
expression vector pIVEX2.4d (Roche), yielding plasmid
pIV2.4SC. The final recombinant fragment of S (SC) contained
an extraneous N-terminal polyhistidine tag. The construct's
insert was confirmed by DNA sequencing using a Big Dye
terminator sequencing kit and an automated sequencer (Applied
Biosystems). Exponentially growing cultures of Escherichia
coli BL21(DE3)pDIA17 cells harboring the pIV2.4SC expres-
sion construct were induced to synthesize the SC polypeptide by
addition of 1 mM isopropyl-β-D-thiogalactoside. Cells were
allowed to grow for 2 h at 30 °C. Under these conditions, the SC
recombinant polypeptide was recovered as inclusion bodies:
cells were harvested and lysed in lysis buffer (0.1 M Tris–HCl
pH 7.5, 1 mM EDTA) using a French press at 1200 psi.
Inclusion bodies in the cell lysate were pelleted by centrifuga-
tion at 20,000×g for 15 min and washed in lysis buffer
supplemented with 2% Triton X100 and 10 mM β-mercap-
toethanol and then in 10 mM Tris–HCl, 7 M urea, pH 7.5 buffer
for 30 min under gentle shaking, before final resuspension in
10 mM Tris–HCl, pH 7.5. The SC protein was obtained at a
purity of more than 90% as determined by SDS-PAGE and
Coomassie blue staining.
New Zealand White rabbits were immunized by intradermal
inoculation with 0.5 mg of recombinant SC polypeptide
emulsified in Incomplete Freund's Adjuvant (Sigma) and
boosted twice at 3 to 4-week intervals. This was followed
3 weeks later by another injection of recombinant SC
polypeptide, which had been further purified on a sucrose
gradient and washed with 2% Triton X100. Immune sera were
collected 5 weeks after the last boost. The antibodies reacted
specifically with the S protein expressed in SARS-CoV infected
VeroE6 cells.
Mouse anti-S polyclonal antibodies
Anti-S antibodies were also raised in mice against the
ectodomain of the S protein, expressed in mammalian cells as a
soluble polypeptide (B. Callendret, V. Lorin, P. Charneau, S.
van der Werf and N. Escriou, unpublished data).
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The first serum sample (sample #033168) was collected
38 days after the onset of symptoms from patient A with
probable SARS, according to the WHO case definition (WHO,
October 2004, posting date). The second set of sera consisted of
one pair of samples that was collected from patient B with
probable SARS, 8 days (sample #032703) and 29 days (sample
#033153) after the onset of symptoms. For both patients A and
B, respiratory tract specimens were tested positive for the
SARS-L gene by nested RT-PCR (Drosten et al., 2003). As a
control, serum samples collected before the 2002 SARS
epidemic were obtained from healthy blood donors (#TV262
and #TV263). All serum samples were inactivated by two
cycles of heating for 30 min at 56 °C and clarified by
centrifugation for 5 min at 15,000×g.
IgG antibodies against the SARS-CoV were present in both
the #033168 and the #033153 serum samples as assayed by
indirect ELISA using crude lysates from SARS-CoV infected
cells as the coating antigen (see below), and there was no non
specific binding of the #TV262 and #TV263 sera to SARS-CoV
antigens.
Analysis of S protein expression in transiently transfected cells
106 Vero E6 cells or 1.4×106 293T cells in 35 mm Petri
dishes under 2 mL of DMEM-5 or DMEM-10 culture medium
respectively were transfected with 2 μg of plasmid DNA and
6 μL of Fugene6 reagent (Roche), according to manufacturer's
instructions and incubated at 37 °C under 5% CO2. Medium
was replaced 24 h later and S expression analyzed at the
indicated time by Western blot, cytofluorometry or immuno-
fluorescence assays.
Alternatively, Vero E6 cells (106 in 35 mm Petri dishes) were
infected at an MOI of 5 with VV-TF7.3 and transfected 1 h later
with 2 μg of either pcDNA-S or pcDNA plasmid DNA as
described above. Vero E6 cells grown in 12 cm2 flasks were
infected with SARS-CoV FFM-1 strain at an MOI of 2 and
incubated in complete DMEM supplemented with 2% FCS at
35 °C under 5% CO2. Total cell lysates were prepared 18 h after
VV-TF7.3 infection or 24 h after SARS-CoV infection, and S
expression was analyzed by Western blot.
Western-blot analysis
For Western blot assays, total cell extracts were harvested
48 h post-transfection in 300 μL of Laemmli sample buffer.
Samples were denatured by heating at 95 °C for 10 min and
sonicated. Proteins were separated by electrophoresis on 8%
SDS-polyacrylamide (prosieve 50, Cambrex) gels, and trans-
ferred onto a PVDF membrane (Amersham). The membrane
was incubated with PBS–0.1% Tween–5% unfatted milk for
1 h at room temperature prior to immunoblotting with rabbit
anti-S polyclonal antibodies. Following incubation with per-
oxydase conjugated anti-rabbit secondary antibody (NA934V,
Amersham) the immunoblot was revealed with enhanced
chemiluminescence (ECL+, Amersham), according to the
manufacturer's instructions and by autoradiography on Hyper-
film (Amersham).Alternatively, the luminescence signals were captured with a
cooled CCD camera (Fluor-S multimager, Bio-Rad). Protein
expression levels were quantified from gel images using the
Quantity One software (v 4.2.3, Bio-Rad).
Northern blot analysis
VeroE6 and 293T cells grown in 35-mm dishes were
transfected as described above. At 24 or 48 h post-transfection,
cell monolayers were washed twice in D-PBS (Invitrogen) and
cellular RNAs were prepared. Total cellular RNAs were isolated
by Trizol-LS extraction (Invitrogen) according to the manufac-
turer's recommendations. For cytoplasmic RNA extraction,
cells were lysed on ice in 10 mM Tris–HCl pH 8.0, 0.14 M
NaCl, 1.5 mM MgCl2, 1 mM DTT, 0.5% NP-40. After 10 min
of incubation at 4 °C, samples were centrifugated at 10,000×g
for 2 min, and the RNAs were purified from the supernatant by
phenol/chloroform extraction and isopropanol precipitation.
The RNAs were treated with DNAse I using the DNA-free kit
(Ambion) according to the manufacturer's recommendations
and stored at −80 °C until use.
After denaturation at 70 °C in 50% formamide, 2.2 M
formaldehyde, 1× running buffer [40 mM MOPS, 10 mM
sodium acetate, 2 mM EDTA, pH 7.0], samples (2 μg) were run
on a 1.2% agarose–0.6 M formaldehyde gel, blotted onto a
nylon membrane (Hybond N, Amersham), and fixed by UV
irradiation. The membranes were hybridized with a mixture of 3
negative sense S-specific 32P-labeled riboprobes corresponding
to nt 21492–22830, 22830–24374 and 24374–25256 of the
SARS-CoV genome. For normalization, the membranes were
hybridized with a β-actin-specific riboprobe. Hybridizations
were performed at 65 °C in a 50% formamide, 5× SSC, 5×
Denhardt, 0.5% SDS solution. The membranes were washed 3
times in 2× SSC, 0.1% SDS at room temperature and another 3
times in 0.1× SSC, 0.1% SDS at 70 °C. Finally, the membranes
were exposed on a STORM 820 phosphorimager (Molecular
Dynamics) and analyzed using the Image Quant program (v 1.2,
Molecular Dynamics).
Cytofluorometry and indirect immunofluorescence assays
For cytofluorometry assays, subconfluent monolayers of
VeroE6 cells and 293Tcells were transfected as described above.
48 h post-transfection, cells were washed once in D-PBS and
detached with 1 mL of cell dissociation solution (Sigma). Cells
were stained with polyclonal mouse anti-S antibody for 45 min
at 4 °C and, after washing, incubated with secondary antibody
(anti-mouse FITC-conjugated, BD Bioscience Pharmingen) for
45 min at 4 °C. Cells were then washed and fixed with PBS–1%
paraformaldehyde. Events were acquired on a FACScalibur
fluorocytometer (Beckton Dickinson) and analyzed with the BD
CellQuest Pro software (v 5.2, Beckton Dickinson).
For indirect immunofluorescence assays, subconfluent
monolayers of VeroE6 cells were transfected as described
above. 24 h post transfection, cells were dissociated with 1 mL
of cell dissociation solution, plated on 20 mm glass coverslips in
a 12 well-plate and incubated in DMEM-5 at 37 °C under 5%
CO2. 24 h later, cells were washed in D-PBS and fixed with
PBS–4% paraformaldehyde for 15 min. Coverslips were then
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2% BSA. After subsequent incubation with a FITC-conjugated
anti-human IgG secondary antibody (Jackson Immunore-
search), the samples were mounted on slides with DAPI-
containing Vectashield (Vector laboratory) and analyzed under
an Axioplan 2 epifluorescence microscope (Zeiss). Pictures
were acquired with an Axiocam MRm camera and processed
with the Axiovision software (v 4.2, Zeiss).
Cell fusion assay
Plasmid pcDNA3-ACE2 encoding the ACE2 molecule,
which is a receptor for SARS-CoV, was obtained from Michael
R. Farzan (Li et al., 2003). 293T cells, constitutively expressing
green fluorescent protein (293T-GFP) were obtained by
transduction of 293T cells with the TRIP-GFP lentiviral vector
(Zennou et al., 2000).
293T-GFP effector cells were transfected either with
plasmids encoding the S glycoprotein or the pCI plasmid as a
control, as described above. In parallel, 293T target cells were
co-transfected with 3 μg of DsRed plasmid DNA and 3 μg of
either pcDNA or pcDNA-ACE2 plasmid DNA using 10 μL
Fugene6 transfection reagent. Medium was replaced 24 h after
transfection. Effector and target cells were detached 12 h later
with cell dissociation solution, resuspended in fresh DMEM-10
and counted. 6×105 per well of each target and effector cells
were plated together in a 12 well-plate with 1 mL of DMEM-10
in each well and co-cultured for 12 h at 37 °C under 5% CO2.
The cells were then trypsinized, fixed with PBS–1% paraf-
ormaldehyde and analyzed on a FACScalibur fluorocytometer.
Fusion was measured as the ratio between double-stained and
red target cells using the BD CellQuest Pro software.
Animal studies
Immunization of mice
Female BALB/c mice (CERJ) 7 to 8 weeks of age were
housed and handled according to the Pasteur Institute guidelines
in compliance with European animal welfare regulations. Mice
were injected intramuscularly with 100 μL PBS (50 μL in each
tibialis anterior muscle) containing plasmid DNA. Mice were
injected with either 50 μg of pCI plasmid DNA as a control, or
variable amounts (2, 10 or 50 μg) of pCI-S, pCI-S-CTE or pCI-
S-WPRE plasmid DNA. Booster injections were administered
at 3 or 4-week intervals. DNA used for injection was prepared
using the EndoFree Plasmid Mega Kit (Qiagen) and tested for
the absence of endotoxin (<5 EU/mg), as measured with the
QCL-1000 Endotoxin kit (BioWhittaker). Blood from mice was
collected 1 week before immunization and 3 weeks after each
injection.
Assays for anti-SARS-CoV antibodies
The induction of SARS-CoV specific antibodies in immu-
nized mice was measured by indirect ELISA and neutralization
assay.
For ELISA, microtiter plates were coated with SARS-CoV
infected or mock-infected Vero E6 crude cell lysates, which hadbeen prepared in a 50 mM Boric Acid, 120 mM NaCl, 1%
Triton X-100 solution at pH 9.0, sonicated in a cup-horn tip,
clarified by centrifugation at 15,000×g for 10 min and
inactivated frozen by gamma irradiation with 50 kGy from a
60Co source. After washing in PBS–0.1% Tween, plates were
incubated with three-fold serial dilutions of mouse sera in PBS-
Tween–3% dry skimmed milk (w/v) starting at 1:16.7 or 1:50.
Bound antibodies were revealed with horseradish peroxidase-
conjugated anti-mouse IgG secondary antibody (Amersham)
and TMB (3,3′-5,5′-tetramethylbenzidine, KPL). The absor-
bance was measured at 450 nm (reference wavelength:
620 nm). Readings from wells coated with mock lysates were
substracted from wells with SARS-CoV lysates and SARS-
CoV specific IgG titers were calculated as the reciprocal of the
highest dilution of individual serum, giving an absorbance
difference of 0.5.
For neutralization assays, two-fold serial dilutions of heat-
inactivated (56 °C, 30 min) serum samples were mixed with 100
TCID50 of SARS-CoV in 100 μL complete DMEM, incubated
at 37 °C for 60 min and added to a subconfluent monolayer of
FRhK-4 cells in a 96-well microtiter plate. Each dilution of
serum as well as positive control (100 TCID50 of SARS-CoV)
and negative cell controls were tested in quadruplicate and
cytopathic effect (CPE) endpoints were read up to 7 days after
inoculation. Neutralizing antibody titers were determined
according to the Reed and Muench method (Reed and Muench,
1938) as the reciprocal of the highest dilution of each serum,
which suppressed CPE in at least 2 out of 4 wells.
Challenge infection of mice with SARS-CoV
Eight weeks after the third plasmid DNA injection, mice
were lightly anaesthetized with Isoflurane (Mundipharma) and
inoculated intranasally with 105 pfu of SARS-CoV in 40 μL
PBS. Mice were euthanized 48 h after challenge infection and
whole lungs crushed in 500 μL DMEM supplemented with 2%
FCS using glass beads and a MM200Mixer Mill (Retsch). After
clarification by low-speed centrifugation for 5 min, lung
homogenates were titrated for infectious virus on VeroE6 cells
monolayers in a standard plaque assay. Challenge infection of
mice and subsequent analysis were done in the “Jean Merieux”
biosafety level 4 containment laboratory. Three mice died
before transfer to the BSL-4 facility, thus could not be
challenged. Statistical analysis was performed on the log10 of
the viral titers measured for individual mice using the Student's
independent t-test, with the assumptions used for small samples
(normal distribution of the variables and same variance for the
populations to be compared).
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